Evidence map›Paper›PMID 40515524›Full record

ArticleFuture oncology (London, England)2025

Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.

Franco Antonio, Luisa Carbognin, Ida Paris, Alba Di Leone, Armando Orlandi, Fabio Marazzi, Antonino Mule, Paolo Belli, Alessandro Rossi, Stefano Magno and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Franco AntonioBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.ORCID 0000-0001-6773-3848
Luisa CarbogninPrecision Medicine Unit in Senology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Ida ParisDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Alba Di LeoneBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Armando OrlandiDepartment of Translational Medicine and Surgery, Medical Oncology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Fabio MarazziUOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Antonino MuleDivision of Anatomic Pathology and Histology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Paolo BelliDiagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Alessandro RossiPrecision Medicine Unit in Senology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Stefano MagnoBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Antonella PalazzoDepartment of Translational Medicine and Surgery, Medical Oncology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Valeria MasielloUOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Angela SantoroDivision of Anatomic Pathology and Histology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Paola FusoDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Emilio BriaDepartment of Translational Medicine and Surgery, Medical Oncology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Sabatino D'ArchiBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Lorenzo ScardinaBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Alejandro Martin SanchezBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Diana GiannarelliEpidemiology and Biostatistics Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Stefano PaternelloReal World Data Facility, Gemelli Generator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Giorgia GarganeseDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Giovanni ScambiaDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Giampaolo TortoraDepartment of Translational Medicine and Surgery, Medical Oncology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Riccardo MasettiBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Gianluca FranceschiniBreast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Alessandra FabiPrecision Medicine Unit in Senology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy (NACT) improves oncologic and cosmetic outcomes in breast cancer (BC), yet recurrence remains a concern. This study identifies factors associated with recurrence at 3 and 5 years in BC patients receiving NACT.

methodsA retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.

resultsLower 5-year EFS was linked to axillary staging (cN,

conclusionBiological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyNeoplasm Recurrence, LocalAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesRisk FactorsBreast cancerchemotherapyneoadjuvantpathological responseprognosisrecurrencesurvival

Identifiers

PMID40515524
PMCPMC12239801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.